背景与目的:贝伐珠单抗是首个抗血管生成的分子靶向药物,可以与多种化疗药物联合用于治疗复发转移性乳腺癌.本研究旨在观察贝伐珠单抗联合多西他赛治疗复发转移性乳腺癌的疗效和不良反应.方法:28例Her-2阴性的复发转移性乳腺癌患者均接受贝伐珠单抗联合多西他赛方案治疗,多西他赛75 mg/m2静滴,第1天:同时给予贝伐珠单抗15 mg/kg,第1天;21 d为1个周期.每个周期评价疗效同时记录不良反应.结果:27例患者可评价疗效和不良反应,其中CR 1例,PR 21例,有效率(CR+PR)为81.5%.粒细胞减少及白细胞减少是主要的不良反应,Ⅳ度粒细胞减少发生率为85.2%.研究中观察到高血压3例,静脉血栓1例,分级均为1级.蛋白尿12例,鼻衄15例,均为1～2级.结论:贝伐珠单抗联合多西他赛是治疗Her-2阴性的复发转移性乳腺癌患者的有效方案,其不良反应能够耐受.%Background and purpose: Bevacizumab has emerged as the first antiangiogenic target drug that can be combined with different cytotoxicity agents to treat metastatic breast cancer. This study evaluated the efficacy and toxicity of bevaizumab in combination with docetaxel for patients with Her-2 negtive metastatic breast cancer. Methods: Twenty-eight patients were selected and treated with bevacizumab (15 mg/kg) in combination with docetaxel (75 mg/m2). All patients received docetaxel 75 mg/m2 iv on d 1 and bevacizumab 15 mg/kg iv on d 1,once every 3 weeks. Results: In 27 assessable patients, we were able to observe 1 complete response and 21 partial responses. Toxicity was generally mild. Grade 3 or 4 hematologic adverse effects were common. The nonhematologic adverse effect included hypertension (n=3), vein thromb (n=l) and proteinurin (n=12). Conclusion: The combination of bevacizumab and docetaxel is an effective regiment for patients with negative Her-2 expression. Overall toxicity is acceptable.
展开▼
